

according to the OSHA Hazard Communication Standard

Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
6.4	09/30/2023	66868-00022	Date of first issue: 02/27/2015

SECTION 1. IDENTIFICATION

Product name	:	Letermovir Liquid Formulation
Manufacturer or supplier's	deta	ails
Company name of supplier Address		Merck & Co., Inc 126 E. Lincoln Avenue Rahway, New Jersey U.S.A. 07065
Telephone Emergency telephone E-mail address	:	908-740-4000 1-908-423-6000 EHSDATASTEWARD@merck.com
Recommended use of the c	hen	nical and restrictions on use
Recommended use Restrictions on use	:	Pharmaceutical Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accord 1910.1200)	GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)		
Reproductive toxicity	:	Category 2	
Specific target organ toxicity - repeated exposure (Oral)	:	Category 2 (Liver, spleen, Blood)	
GHS label elements			
Hazard pictograms	:		
Signal Word	:	Warning	
Hazard Statements	:	H361d Suspected of damaging the unborn child. H373 May cause damage to organs (Liver, spleen, Blood) through prolonged or repeated exposure if swallowed.	
Precautionary Statements	:	 Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe mist or vapors. P280 Wear protective gloves, protective clothing, eye protection and face protection. Response: P308 + P313 IF exposed or concerned: Get medical attention. Storage: P405 Store locked up. 	





Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
6.4	09/30/2023	66868-00022	Date of first issue: 02/27/2015

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture	: Mixture	
Components		
Chemical name	CAS-No.	Concentration (% w/w)
Letermovir	917389-32-3	>= 1 - < 5

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	
Protection of first-aiders	:	
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam
		Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.



according to the OSHA Hazard Communication Standard

Letermovir Liquid Formulation

Versi 6.4	on Revision Date: 09/30/2023)S Number: 868-00022	Date of last issue: 04/04/2023 Date of first issue: 02/27/2015
1	Specific hazards during fire ighting Hazardous combustion prod- ucts	:		pustion products may be a hazard to health.
	Specific extinguishing meth- ods	:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do
	Special protective equipment or fire-fighters	:		e, wear self-contained breathing apparatus. ective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	:	Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures	:	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	:	Use only with adequate ventilation.
Advice on safe handling	:	Do not breathe mist or vapors.
		Do not swallow.
		Avoid contact with eyes.
		Avoid prolonged or repeated contact with skin.
		Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure



according to the OSHA Hazard Communication Standard

Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
6.4	09/30/2023	66868-00022	Date of first issue: 02/27/2015
	litions for safe storage rials to avoid	environment. : Keep in proper Store in accord	revent spills, waste and minimize release to the ly labeled containers. lance with the particular national regulations. th the following product types: g agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components		CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Letermovir		917389-32-3	TWA	0.4 mg/m3 (OEB 2)	Internal
Engineering measures	:	technologies t less quick cor All engineerin design and op protect produc	o control airbor inections). g controls shou perated in accor cts, workers, an	controls and manufact re concentrations (e.) Id be implemented by dance with GMP print d the environment. require special conta	g., drip- facility ciples to
Personal protective equipn	nent				
Respiratory protection	:	maintain vapo concentration unknown, app Follow OSHA use NIOSH/M by air purifying hazardous ch supplied respi release, expo	r exposures be s are above recorropriate respirator respirator regu SHA approved g respirators ag emical is limited rator if there is sure levels are where air purify	entilation is recommen- low recommended lim commended limits or a atory protection should lations (29 CFR 1910 respirators. Protection jainst exposure to any d. Use a positive press any potential for unco unknown, or any othe ving respirators may n	hits. Where are d be worn. .134) and n provided sure air ontrolled r
Hand protection Material	:	Chemical-resi	stant gloves		
Eye protection	:	If the work en mists or aeros Wear a faces	vironment or ac sols, wear the a nield or other fu	e shields or goggles. ctivity involves dusty c ppropriate goggles. Il face protection if the the face with dusts, m	ere is a
Skin and body protection Hygiene measures	:	Work uniform If exposure to	ystems and saf	oat. ely during typical use, ety showers close to t	

Ingredients with workplace control parameters





Letermovir Liquid Formulation

Version 6.4	Revision Date: 09/30/2023		S Number: 368-00022	Date of last issue: 04/04/2023 Date of first issue: 02/27/2015
			Wash contaminate The effective oper engineering control appropriate degov	ot eat, drink or smoke. ed clothing before re-use. ration of a facility should include review of ols, proper personal protective equipment, wning and decontamination procedures, monitoring, medical surveillance and the ive controls.
SECTIC	ON 9. PHYSICAL AND CHE	ΞΜΙΟ	CAL PROPERTIES	5
Арј	pearance	:	liquid	
Co	lor	:	clear	
Od	or	:	odorless	
Od	or Threshold	:	No data available)
рH		:	7.5	
Me	Iting point/freezing point	:	No data available)
Init ran	ial boiling point and boiling ge	:	No data available	
Fla	sh point	:	No data available)
Eva	aporation rate	:	No data available)
Fla	mmability (solid, gas)	:	Not applicable	
Fla	mmability (liquids)	:	No data available)
	per explosion limit / Upper nmability limit	:	No data available	
	ver explosion limit / Lower nmability limit	:	No data available	
Vaj	por pressure	:	No data available	2
Re	lative vapor density	:	No data available)
Re	lative density	:	No data available)
De	nsity	:	No data available)
	ubility(ies) Water solubility	:	No data available)
	rtition coefficient: n- anol/water	:	Not applicable	
	anoi/water toignition temperature	:	No data available	3



according to the OSHA Hazard Communication Standard

Letermovir Liquid Formulation

Version 6.4	Revision Date: 09/30/2023		S Number: 68-00022	Date of last issue: 04/04/2023 Date of first issue: 02/27/2015
Decor	mposition temperature	:	No data available	e
	sity scosity, kinematic sive properties	:	No data available Not explosive	e
	zing properties le size	:	The substance o	r mixture is not classified as oxidizing.

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac- tions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
Components:		
Letermovir: Acute oral toxicity	:	LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Letermovir:



according to the OSHA Hazard Communication Standard

Letermovir Liquid Formulation

rsion I	Revision Date: 09/30/2023	SDS Number:Date of last issue: 04/04/202366868-00022Date of first issue: 02/27/2015
Rema	arks	: No data available
Not cl	us eye damage/eye lassified based on ava conents:	
Leter Rema	movir: arks	: No data available
Resp	iratory or skin sensi	tization
	sensitization lassified based on ava	ailable information.
-	iratory sensitization assified based on ava	
<u>Comp</u>	oonents:	
Leter Rema	movir: arks	: No data available
	a cell mutagenicity lassified based on ava	ailable information.
Not cl	• •	ailable information.
Not cl <u>Comp</u> Leter	assified based on ava	ailable information. : Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Not cl <u>Comp</u> Leter	lassified based on ava ponents: movir:	: Test Type: Bacterial reverse mutation assay (AMES)
Not cl <u>Comr</u> Leter Geno	lassified based on ava ponents: movir:	 Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosome aberration test in vitro
Not cl <u>Comp</u> Leter Geno Geno	lassified based on ava <u>conents:</u> movir: toxicity in vitro	 Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosome aberration test in vitro Result: negative Test Type: Mammalian erythrocyte micronucleus test (in v cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection
Not cl <u>Comp</u> Leter Geno Geno Germ Asses	lassified based on ava <u>conents:</u> movir: toxicity in vitro toxicity in vivo cell mutagenicity -	 Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosome aberration test in vitro Result: negative Test Type: Mammalian erythrocyte micronucleus test (in v cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Result: negative Weight of evidence does not support classification as a get
Not cl Comp Leter Geno Geno Germ Asses	lassified based on ava <u>conents:</u> movir: toxicity in vitro toxicity in vivo cell mutagenicity - ssment nogenicity lassified based on ava No ingredie	 Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosome aberration test in vitro Result: negative Test Type: Mammalian erythrocyte micronucleus test (in v cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Result: negative Weight of evidence does not support classification as a ge cell mutagen.
Not cl <u>Comp</u> Leter Geno Geno Germ Asses Carci Not cl	lassified based on ava <u>conents:</u> movir: toxicity in vitro toxicity in vivo cell mutagenicity - ssment nogenicity lassified based on ava No ingredie identified a No compor	 Test Type: Bacterial reverse mutation assay (AMES) Result: negative Test Type: Chromosome aberration test in vitro Result: negative Test Type: Mammalian erythrocyte micronucleus test (in v cytogenetic assay) Species: Mouse Application Route: Intraperitoneal injection Result: negative Weight of evidence does not support classification as a ge cell mutagen.



according to the OSHA Hazard Communication Standard

Letermovir Liquid Formulation

Version 6.4	Revision Date: 09/30/2023		DS Number: 868-00022	Date of last issue: 04/04/2023 Date of first issue: 02/27/2015				
	identified as a	a kn	own or anticipated	carcinogen by NTP.				
	Reproductive toxicity Suspected of damaging the unborn child.							
<u>Co</u>	<u>mponents:</u>							
	ermovir: ects on fertility	:	Species: Rat, fem Application Route	: Oral 240 mg/kg body weight				
			Species: Rat, mal Application Route Fertility: LOAEL: Result: No effects	: Oral 180 mg/kg body weight				
			Species: Monkey Application Route	: Oral 240 mg/kg body weight				
Effe	ects on fetal development	:	Species: Rat Developmental To Result: Embryo-fe	ro-fetal development oxicity: LOAEL: 250 mg/kg body weight etal toxicity. al toxicity observed.				
			Species: Rabbit Developmental To Result: Embryo-fe Abortion	ro-fetal development oxicity: LOAEL: 225 mg/kg body weight etal toxicity., Malformations were observed., al toxicity observed.				
	productive toxicity - As- sment	:	Some evidence o animal experimen	f adverse effects on development, based on tts.				

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Liver, spleen, Blood) through prolonged or repeated exposure if swallowed.

according to the OSHA Hazard Communication Standard



Letermovir Liquid Formulation

ersion 4	Revision Date: 09/30/2023	SDS Number: 66868-00022	Date of last issue: 04/04/2023 Date of first issue: 02/27/2015
<u>Comp</u>	oonents:		
Leter	movir:		
	s of exposure	: Ingestion	
	t Organs	: Liver, splee	en. Blood
	sment		damage to organs through prolonged or repeated
Repe	ated dose toxicity		
Comp	oonents:		
Leter	movir:		
Speci		: Mouse	
NOAE		: 40 mg/kg	
LOAE		: 100 mg/kg	
	ation Route	: Oral : 13 Weeks	
	sure time t Organs	: Liver, splee	an an
rarge	t Organs		
Speci		: Rat	
NOAE		: 150 mg/kg	
	ation Route	: Oral	
Rema	sure time rks	: 26 Weeks	ant adverse effects were reported
Rema		. No signifio	
Speci		: Monkey	
NOAE		: 100 mg/kg	
LOAE		: 200 - 250 r	ng/kg
	ation Route	: Oral : 39 Weeks	
	t Organs	: Kidney	
-	-		
Speci NOAE		: Rat : 60 mg/kg	
LOAE		: 180 mg/kg	
	sure time	: 13 Weeks	
	t Organs		od, Liver, spleen, Immune system
Speci	es	: Monkey	
NOAE		: 30 mg/kg	
LOAE		: 100 mg/kg	
	ation Route	: Oral	
	sure time	: 4 Weeks	
Targe	t Organs	: Blood	

Not classified based on available information.

Experience with human exposure

Components:

Letermovir:





Letermovir Liquid Formulation

Version 6.4	Revision Date: 09/30/2023	SDS Number: 66868-00022	Date of last issue: 04/04/2023 Date of first issue: 02/27/2015
Inges	tion		arrhea, Nausea, Vomiting, Headache, Dizzi- Back pain, Edema, Rash, muscle pain
SECTION 12. ECOLOGICAL I		IFORMATION	
	oxicity ponents:		

Letermovir:		
Toxicity to fish	:	LC50 (Menidia beryllina (Silverside)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Americamysis): 16 mg/l Exposure time: 96 h
		EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 8.8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility.
		NOEC (Pseudokirchneriella subcapitata (green algae)): 8.8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility.
Toxicity to fish (Chronic tox- icity)	:	NOEC (Pimephales promelas (fathead minnow)): 1 mg/l Exposure time: 32 d Method: OECD Test Guideline 210 Remarks: No toxicity at the limit of solubility.
Toxicity to daphnia and other aquatic invertebrates (Chron-ic toxicity)	:	NOEC (Daphnia magna (Water flea)): 1.2 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
Toxicity to microorganisms	:	EC50: > 972 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
		NOEC: 29.6 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209



according to the OSHA Hazard Communication Standard

Letermovir Liquid Formulation

Versio 6.4	on	Revision Date: 09/30/2023		DS Number: 868-00022	Date of last issue: 04/04/2023 Date of first issue: 02/27/2015
P	Persist	ence and degradabil	ity		
<u>c</u>	Compo	<u>nents:</u>			
L	.eterm	ovir:			
В	Biodegr	adability	:	Result: rapidly de Biodegradation: Exposure time: 6.	50 %
В	Bioaccu	umulative potential			
<u>c</u>	Compo	nents:			
P	etermo Partition	n coefficient: n-	:	log Pow: 2.29	
Μ	/lobility	/ in soil			
<u>c</u>	Compo	nents:			
D		ovir: tion among environ- compartments	:	log Koc: 3.46	
-		dverse effects available			
SECT	ION 13	B. DISPOSAL CONSI	DEF	ATIONS	

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods		
Waste from residues	:	Dispose of in accordance with local regulations. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR





Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last is
6.4	09/30/2023	66868-00022	Date of first is

Date of last issue: 04/04/2023 Date of first issue: 02/27/2015

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

Listed substances in the product are at low enough levels to not be expected to exceed the RQ

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards	:	Reproductive toxicity Specific target organ toxicity (single or repeated exposure)
SARA 313	:	This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know						
	Water		7732-18-5			
	Hydroxypropyl-beta–c Hydrochloric acid	cyclodextrin	128446-35-5 7647-01-0			
The ingredients of this product are reported in the following inventories:						
AICS	:	not determined				
DSL	:	not determined				
IECSC	:	not determined				


SECTION 16. OTHER INFORMATION

Further information



according to the OSHA Hazard Communication Standard

Letermovir Liquid Formulation



Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act



according to the OSHA Hazard Communication Standard

Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
6.4	09/30/2023	66868-00022	Date of first issue: 02/27/2015
Transp Source	oort of Dangerous Good es of key data used to e the Material Safety	ds; vPvB - Very Persis : Internal technical	- United Nations Recommendations on the tent and Very Bioaccumulative data, data from raw material SDSs, OECD arch results and European Chemicals Agen- ropa.eu/

Revision Date : 09/30/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8